Brief: Medipost receives patent
13/09/2017 17:20
Sept 14 (Reuters) - Medipost Co Ltd 078160.KQ :
* Says it received patent on Sep. 13, for pharmaceutical
composition for the prevention or treatment of a lung disease
comprising mesenchymal stem cells having improved proliferation
and differentiation capacity
* Patent number is 10-2016-0025484
Source text in Korean: https://goo.gl/1Cua5m
Further company coverage: 078160.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America